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Introduction: T cell bispecific antibodies (TCB) are designed to recruit and
simultaneously activate T cells against target cells such as tumor cells expressing a
particular surface antigen. However, it is currently unknown how immuno-modulatory
mechanisms active in the tumor microenvironment such as the expression of T cell
co-inhibitory receptors may influence the therapeutic effect of TCBs.
Methods:We performed a comprehensive phenotypic analysis of tumor infiltrating
immune cells from lung carcinoma digests by multicolour flow cytometry. In
particular, expression of T cell co-inhibitory and -stimulatory receptors was analyzed.
Tumor digests were treated with catumaxomab, a TCB directed against CD3 and
EpCAM. T cell activation and effector functions were assessed upon exposure to
catumaxomab.
Results: CD8+ T cells in lung carcinoma showed a broad heterogeneity in expression of
the T cell co-inhibitory receptors PD-1, Tim-3, CTLA-4, Lag-3 and BTLA. Tumor
stage and nodal status correlated with number and intensity of expressed receptors.
Upon exposure to catumaxomab, a considerable heterogeneity in T cell activation
among different tumors was observed. Of note, T cells expressing high levels and
multiple co-inhibitory receptors were more impaired in their activation and effector
functions after treatment with catumaxomab indicating a higher level of exhaustion. In
a further analysis of CD8+ TIL subsets we found that BTLA+ T cells expressed more
additional inhibitory receptors than all other subsets, namely PD-1, Tim-3, CTLA-4
and Lag-3, whereas only a small part of PD-1+ T cells expressed another receptor.
Tim-3+ T cells usually co-expressed PD-1, but multiple receptors were found only on a
low number of cells.
Conclusion: In summary, our data suggest that the activity of TCBs is largely affected
by the expression of T cell co-inhibitory receptors on tumor-infiltrating immune cells.
Furthermore, these data provide a clinical rationale for combining bispecific antibodies
with compounds which antagonize T cell exhaustion.
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